n.achebe

TL2 · Verona

Contributes reviews on supplier material. Based in Verona.

Joined 24 December 2024 · last posted 5d

78Posts here

3Topics

1Solutions

262Likes received

135Likes given

20Badges

129Days visited

1.2kPosts read

Recent activity

Full stream

Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #55 · Analytics › Home & field testing · 23 Jul 2026 · 0 likes The claim about home kit substitute upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #7 · Practice › Administration · 15 Jul 2026 · 7 likes Note the site alongside the dose. If a local reaction appears three weeks later you will want to know where the previous four injections went. That has held every time…
Follow-up: How compounding permissions changed when supply normalised Replied, post #11 · Sourcing › Regulatory · 11 Jul 2026 · 8 likes Compounding permissions: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #67 · Analytics › Impurities & related substances · 11 Jul 2026 · 29 likes Post #63 put the caveat in the right place and I want to underline it. Where an impurity is identified rather than merely counted, the certificate is telling you the…
Pages past their review date, listed — does this still hold? Replied, post #31 · Meta › Wiki maintenance · 30 Jun 2026 · 5 likes Two questions I would want answered before drawing anything from the Pages past data above: how were the cases selected, and what happened to the ones that dropped out.
Mobile reading experience on long topics Replied, post #2 · Meta › Site feedback · 24 Jun 2026 · 19 likes Narrowing the opening post, because the general version has more than one answer. Feature request framed as feedback: the category list is long enough that a first-time…
An appeal that succeeded, with the letter structure Replied, post #10 · Access › Insurance & coverage · 22 Jun 2026 · 0 likes Where an exception process exists separately from an appeal, they are different routes with different criteria and using the wrong one loses time. Noting that the…
Pooling trials with different estimands Replied, post #31 · Evidence › Meta-analyses · 17 Jun 2026 · 25 likes Fixed-effects versus random-effects models: fixed-effects assumes all studies are estimating the same thing and variation is sampling error. Random-effects assumes…
Primary endpoint hierarchies and why order matters — one year on Replied, post #16 · Evidence › Trials · 15 Jun 2026 · 3 likes The figure that circulates in coverage is almost always whichever estimand gives the larger effect. That is not fraud; it is selection, and it is why the paper matters…
Journal club: what we got wrong in an earlier session Started this topic · Evidence › Journal club · 11 Jun 2026 · 13 likes On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Bringing a claim rather than a paper, because…
Does dual agonism explain the effect size, or is it dose? Replied, post #23 · Compounds › Tirzepatide · 8 Jun 2026 · 0 likes Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #26 · Evidence › Journal club · 24 May 2026 · 0 likes I would put moderate confidence on the mainstream reading of STEP 1 and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.